Company: RNAC
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001453687-25-000120
Chunk: 39

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 39
---
 to purchase common stock692,523 974,954 692,523 974,954 Series A Preferred Stock4,026,346 5,544,719 4,026,346 5,544,719 Series B Preferred Stock437,927 437,927 437,927 437,927 Total8,113,706 9,378,000 8,113,706 9,378,000 

14

7. Fair Value Measurements

The following tables present the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2025 and December 31, 2024 (in thousands):September 30, 2025TotalLevel 1Level 2Level 3Assets:Money market funds (included in cash equivalents)$40,357 $40,357 $— $— Total assets$40,357 $40,357 $— $— Liabilities:Warrant liability$848 $— $— $848 Contingent value right liability369,000 — — 369,000 Total liabilities$369,848 $— $— $369,848 December 31, 2024TotalLevel 1Level 2Level 3Assets:Money market funds (included in cash equivalents)$39,088 $39,088 $— $— Total assets$39,088 $39,088 $— $— Liabilities:Warrant liability$3,836 $— $— $3,836 Contingent value right liability395,500 — — 395,500 Total liabilities$399,336 $— $— $399,336 There were no transfers within the fair value hierarchy during the nine months ended September 30, 2025 or the year ended December 31, 2024.Cash, Cash Equivalents, and Restricted CashAs of September 30, 2025 and December 31, 2024, money market funds were classified as cash and cash equivalents on the accompanying consolidated balance sheets as they mature within 90 days from the date of purchase.As of September 30, 2025, the Company had restricted cash balances relating to secured letters of credit in connection with its real estate leases. The Company’s consolidated statements of cash flows include the following as of September 30